Key result
Ambulatory management of deep vein thrombosis with tinzaparin was associated with a 2.5% rate of thromboembolic complications and a 3.4% rate of bleeding complications at 6 months.
Why the study?
Is ambulatory treatment of DVT with tinzaparin safe and effective in a real-world setting?
Cohort (n=697)
Yes
Is ambulatory treatment of DVT with tinzaparin safe and effective in a real-world setting?
Ambulatory management of DVT with tinzaparin in a real-world setting demonstrates low rates of thromboembolic and bleeding complications, comparable to clinical trial data.
Answers are grounded in this paper and cite their sources.
Supports ambulatory DVT management with tinzaparin in selected patients; extends trial data to real-world cohorts but leaves open need for randomized confirmation.
Low molecular weight heparins (LMWHs) have been demonstrated to be at least as safe and effective as unfractionated heparin (UFH) in the initial management of deep vein thrombosis (DVT). However, the effectiveness of using LMWH in the ambulatory management of DVT in a 'real-life' setting has yet to be evaluated. This multicentre retrospective study involving 697 patients considers the outcome data of patients under- going ambulatory DVT treatment with tinzaparin (Innohep(R), Leo Pharmaceuticals, Risborough, Buckinghamshire, UK). During the 6 months following presentation, 17 (2.5%) patients had confirmed thromboembolic complications, of which 14 occurred subsequent to the initial LMWH treatment phase ('late'). There were no deaths in this group. Bleeding complications were reported in 23 (3.4%) patients, with 13 of these being classified as 'late'. Of these, two events were considered major resulting in hospitalization and death. Hospitalization for all causes was 6.8% (45 patients) with 32 patients being admitted for thromboembolic or bleeding complications. Overall mortality was 6.7%. These results compare favourably with published clinical trial data. This study demonstrates that ambulatory treatment of proven DVT with LMWH is both safe and effective.
No takes yet. Share an insight, caveat, or question.
Rose et al. (2001) conducted a cohort in deep vein thrombosis (DVT) (n=697). Tinzaparin was evaluated on confirmed thromboembolic complications. Ambulatory management of deep vein thrombosis with tinzaparin was associated with a 2.5% rate of thromboembolic complications and a 3.4% rate of bleeding complications at 6 months.
Synapse has enriched 10 related papers. Consider them for comparative context: